ReCode Therapeutics, a clinical-stage company powering the next wave of genetic medicines, today announced that Company management will participate in the following upcoming investor conferences in September 2023:

Morgan Stanley Global Healthcare Conference:

Format: Company Presentation

Date: September 12, 2023

Time: 12:55 p.m. ET

Presenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics

Location: New York, NY

Jefferies Cell & Genetic Medicine Summit

Format: Company Presentation

Date: September 26, 2023

Time: 10:30 a.m. ET

Presenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics

Location: New York, NY

BMO Biopharma Spotlight Series: Latest Advances in Genome/Epigenome Editing

Format: Panel Discussion - Novel Approaches in Gene Editing and Delivery

Date: September 26, 2023

Time: 2:30 p.m. ET

Presenter: Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics

Location: Virtual

About ReCode Therapeutics

ReCode Therapeutics is a clinical-stage company powering the next wave of genetic medicines. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. In 2022, ReCode was named among Fierce Biotech’s “Fierce 15” as one of the most promising early-stage biotechnology companies in the industry and was described by Nature as one of the “Seven Technologies to Watch in 2022” for its SORT LNP platform. For more information, visit www.recodetx.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230907573518/en/